Novo Nordisk Raises Full-Year Outlook on GLP-1 Momentum, Q3 Profit Jumps 27%
Event summary
- Q3 2026 adjusted operating profit increased 27% at CER to DKK 31,720 million, driven by GLP-1 sales growth and favorable comparison base.
- Reported operating profit decreased 9% at CER due to DKK 8.7 billion in non-cash impairment charges related to ziltivekimab and manufacturing network right-sizing.
- Wegovy® pill launched in 8 markets, maintaining over 50% US market share in branded obesity.
- Ozempic® pill launched in the US in May, with weekly new-to-brand prescriptions up around 100% compared to pre-launch levels.
- Full-year outlook raised: adjusted sales and operating profit growth now expected to be -2% to +2% at CER.
The big picture
Novo Nordisk's strong Q3 performance underscores the continued dominance of GLP-1 therapies in the obesity and diabetes markets. The company's ability to raise its full-year outlook despite impairment charges highlights the resilience of its core franchises. The strategic focus on expanding access and advancing the pipeline positions Novo Nordisk to maintain its leadership in a highly competitive landscape. The global roll-out of next-generation products like Ozempic® 2.0 mg and Wegovy® 7.2 mg single-dose pen will be key to sustaining growth.
What we're watching
- Pipeline Execution
- The pace at which CagriSema and zenagamtide advance through clinical trials will determine Novo Nordisk's long-term competitive edge in obesity and diabetes treatments.
- Regulatory Dynamics
- The timing and outcome of the EU approval for Frehemgo® and the US regulatory review for denecimig will impact Novo Nordisk's ability to expand its portfolio in blood and endocrine disorders.
- Market Penetration
- Whether Novo Nordisk can sustain the momentum of Wegovy® and Ozempic® in international markets will be critical for meeting revised full-year outlook expectations.
Related topics
